Skip to main content

TABLE 1.

Patient characteristics and HCVNS3-1073 and HCVNS3-1406 peptide-specific cytotoxic activity of T-cell lines derived from PBMC of patients with chronic hepatitis C

Patient HCV genotype HCV RNA (106 copies/ml) ALTa (U/ml) Liver histologyb
Specific lysis (%) ofc:
Inflammatory score Fibrosis score HCVNS3-1073-loaded target cells HCVNS3-1406-loaded target cells
Chr-1 1b 30.9 25 7 0 48 29
Chr-2 2b 6.1 35 9 0 59 53
Chr-3 2b 4.7 14 NDd ND 19 5
Chr-4 1b 0.4 18 5 0 6 2
Chr-5 2b 43 25 ND ND 43 8
Chr-6 1a 7.0 27 3 0 0 0
Chr-7 UGe 43.1 32 ND ND 3 4
Chr-8 1b 1.3 22 ND ND 27 7
Chr-9 1b 0.2 22 ND ND 44 12
Chr-10 2b 6.0 20 ND ND 2 21
Chr-11 1a 0.3 60 6 0 42 42
Chr-12 1a 21.1 59 8 1 44 36
Chr-13 1a 1.2 55 6 0 9 43
Chr-14 1a 6.4 40 5 0 2 5
Chr-15 1b 0.5 50 7 1 3 3
Chr-16 1a 0.5 91 3 0 18 15
Chr-17 1a 2.5 55 6 0 2 28
Chr-18 1a 31.7 69 ND ND 3 16
Chr-19 1a 6.8 51 7 1 38 0
Chr-20 1a 1.4 49 7 0 48 26
 No. of patients positive/total (% positive) 11/20 (55) 11/20 (50)
 Mean cytotoxicityf ± SD 39 ± 12 29 ± 12
a

ALT, alanine aminotransferase. 

b

Liver biopsy specimens were scored according the HAI score introduced by Knodell et al. (19b). Inflammatory score, i.e., histological inflammatory activity score, 0 to 14; fibrosis score, 0 to 4. All liver biopsies were performed within 3 months of the immunologic analysis. 

c

The specific cytotoxic activity of peptide-stimulated cell lines was tested at an effector/target cell ratio of 30:1. Responses with a specific lysis of >10% were considered to be positive and are shown in boldface. Cell lines tested for HCVNS3-1073-specific cytotoxicity had been stimulated with peptide HCVNS3-1073; cell lines tested for HCVNS3-1406-specific cytotoxicity had been stimulated with peptide HCVNS3-1406

d

ND, not done. 

e

UG, unable to genotype. 

f

The mean cytotoxicity of all positive T-cell lines was calculated.